MorphoSys AG (WBO:MOR) Price-to-Operating-Cash-Flow : (As of Apr. 28, 2024)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Price-to-Operating-Cash-Flow?

As of today (2024-04-28), MorphoSys AG's share price is €67.80. MorphoSys AG's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-5.77. Hence, MorphoSys AG's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for MorphoSys AG's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, MorphoSys AG's highest Price-to-Operating-Cash-Flow Ratio was 429.28. The lowest was 13.99. And the median was 25.29.

WBO:MOR's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.65
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

MorphoSys AG's Cash Flow from Operations per share for the three months ended in Dec. 2023 was €0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-5.77.

During the past 13 years, MorphoSys AG's highest 3-Year average Operating Cash Flow per Share Growth Rate was 251.40% per year. The lowest was -139.70% per year. And the median was -5.30% per year.

MorphoSys AG Price-to-Operating-Cash-Flow Historical Data

The historical data trend for MorphoSys AG's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Price-to-Operating-Cash-Flow Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

88.26

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of MorphoSys AG's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, MorphoSys AG's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Price-to-Operating-Cash-Flow falls into.

MorphoSys AG Price-to-Operating-Cash-Flow Calculation

MorphoSys AG's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	67.80	/	-5.772
	=

MorphoSys AG's Share Price of today is €67.80.
MorphoSys AG's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.77.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

MorphoSys AG Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.